Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

Area of Science:

• Molecular oncology
• Cancer genetics
• Epigenetics and chromatin remodeling

Background:

• The ARID1A gene, a chromatin remodeler, is frequently mutated in various cancers, including over 50% of ovarian clear cell carcinomas.
• Ovarian clear cell carcinomas with ARID1A mutations currently lack effective targeted therapies.
• No clinically applicable targeted cancer therapies based on ARID1A mutational status have been established.

Purpose of the Study:

• To investigate the potential of targeting EZH2 in ARID1A-mutated ovarian cancer cells.
• To identify therapeutic strategies for ARID1A-mutated cancers.
• To explore the synthetic lethal interaction between ARID1A mutations and EZH2 inhibition.

Main Methods:

• Utilized cell-based assays to assess the effect of EZH2 inhibition on ARID1A-mutated ovarian cancer cells.
• Investigated the molecular mechanisms underlying the synthetic lethality, including the role of PIK3IP1 and PI3K-AKT signaling.
• Evaluated the in vivo efficacy of EZH2 inhibition in ARID1A-mutated ovarian tumor models.

Main Results:

• EZH2 inhibition demonstrated synthetic lethality in ARID1A-mutated ovarian cancer cells.
• ARID1A mutational status correlated with response to EZH2 inhibition.
• PIK3IP1 was identified as a direct target of ARID1A and EZH2, upregulated by EZH2 inhibition, contributing to synthetic lethality by suppressing PI3K-AKT signaling. EZH2 inhibition led to tumor regression in vivo.

Conclusions:

• This study presents the first evidence of synthetic lethality between ARID1A mutation and EZH2 inhibition.
• Pharmacological inhibition of EZH2 represents a novel and promising therapeutic strategy for cancers with ARID1A mutations.
• The findings open new avenues for treating ARID1A-mutated ovarian clear cell carcinomas.